Table 2.
Effects of moderate-intensity cyclic hypoxic training on cardiorespiratory capacity and monitoring variables of the incremental test of patients recovered from COVID-19
| Time | Group | Time × Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| BSLN | 8W | Diff | P Value | η2 | P Value | η2 | P Value | η2 | |
| VO2peak (mL/min) | |||||||||
| CG | 1801.8 (414.7) | 1843.6 (479.2) | 41.8 | ||||||
| NG | 1763.3 (634.2) | 2058.6 (713.5)* | 295.3 | <0.01 | 0.039 | 0.85 | 0.007 | 0.01 | 0.015 |
| HG | 1764.1 (428.4) | 2051.1 (478.2)** | 287.0 | ||||||
| VO2peak (mL/kg/min ) | |||||||||
| CG | 21.6 (5.7) | 21.9 (6.4) | 0.3 | ||||||
| NG | 22.1 (6.5) | 26.0 (8.3) | 3.9 | <0.01 | 0.481 | 0.61 | 0.024 | <0.01 | 0.301 |
| HG | 20.1 (5.2) | 23.6 (8.3) | 3.5 | ||||||
| iVO2peak (watts) | |||||||||
| CG | 106.3 (41.2) | 113.5 (42.9) | 7.2 | ||||||
| NG | 95.7 (52.4) | 131.0 (57.7)** | 35.3 | <0.01 | 0.062 | 0.79 | 0.010 | <0.01 | 0.017 |
| HG | 106.7 (36.2) | 133.0 (37.6)** | 26.3 | ||||||
| [La]peak (mM) | |||||||||
| CG | 6.8 (1.7) | 5.7 (1.6) | -1.1 | ||||||
| NG | 6.2 (2.5) | 6.9 (1.9) | 0.6 | 0.94 | 3.556-5 | 0.55 | 0.021 | 0.02 | 0.049 |
| HG | 6.6 (2.2) | 7.1 (1.7) | 0.6 | ||||||
| HRpeak (bpm) | |||||||||
| CG | 151.5 (18.1) | 149.3 (17.4) | -2.2 | ||||||
| NG | 160.2 (17.6) | 158.4 (13.2) | -1.8 | 0.78 | 3.372-4 | 0.21 | 0.062 | 0.60 | 0.004 |
| HG | 156.6 (13.7) | 158.8 (13.2) | 2.2 | ||||||
| RPEpeak | |||||||||
| CG | 8.7 (1.4) | 9.2 (1.5) | 0.5 | ||||||
| NG | 8.6 (1.6) | 7.2 (2.3) | -1.4 | <0.01 | 0.044 | 0.16 | 0.057 | <0.01 | 0.071 |
| HG | 9.6 (0.9) | 8.2 (2.4)* | -1.4 | ||||||
BSLN, baseline; CG, control group; COVID-19, coronavirus disease 2019; Diff, difference; 8W, 8 weeks; η2, effect size; HG, hypoxia group; HR, heart rate; iVO2, VO2 intensity; [La], lactate concentration; NG, normoxia group; P, significance level; RPE, rate of perceived exertion; VO2, oxygen uptake.
Data presented as mean (SD).
*
P < 0.05, **P < 0.01 between BSLN and 8W in the same group.